Xarelto: A new ray of hope for peripheral arterial disease
Peripheral arterial disease (PAD) is a common form of the atherosclerotic disease. The pharmacological management of PAD encompasses the use of a wide... In DRG Blog, Drug Watch/ September, 2018 ESC 2018 Highlights: Sink or Sail for Xarelto?
Continuing in tradition, this year’s European Society of Cardiology (ESC) Congress, which was held during August 25-29 in Munich, again witnessed an... In DRG Blog, Drug Watch/ August, 2018 ESC 2017 Roundup: What’s on the Horizon for Atrial Fibrillation?
The European Society of Cardiology (ESC) Congress 2017 took place in sunny Barcelona, Spain last month from August 26th to August 30th. The event... In DRG Blog, Drug Watch/ September, 2017 Market Outlook for Betrixaban: Assessing Portola’s ‘Flagship’ Product in The Medically Ill Patient Population
Portola pharmaceutical’s betrixaban, an oral, once daily factor Xa inhibitor anticoagulant, has been receiving a lot of attention following the... In DRG Blog, Drug Watch/ June, 2017